Sierra Believes It Can Do Better Than Gilead With JAK Inhibitor Momelotinib
With many on the executive team who worked on the drug previously, Sierra thinks the stalled Phase III compound could be differentiated from Jakafi and others in the myelofibrosis space based on anemia benefit.
You may also be interested in...
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
There have been lots of twists and turns on the development path for Inrebic which is now the second JAK inhibitor to be approved in the EU for MF since the blockbuster Jakavi was cleared in 2012.
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.